Summary5 min read

The Peter Attia Drive – Episode #398:

AMA #86: GLP-1 RAs and Muscle Loss – New Data, Better Questions, and How to Preserve Muscle During Weight Loss
Release Date: June 29, 2026
Host: Dr. Peter Attia
Guest/Co-Host: Bob

Episode Overview

In AMA #86, Dr. Peter Attia delves into the complex relationship between GLP-1 receptor agonists (GLP-1 RAs)—medications like Ozempic, Wegovy, and Zepbound—and muscle loss during weight loss. The episode explores not just how these drugs promote weight loss, but importantly, the specific effects on lean mass (muscle and bone), bone health, metabolic outcomes, and how patients and clinicians can optimize the preservation of muscle during pharmacologically-induced weight loss.

Key Topics & Insights

1. Evolution of GLP-1 RA Use and Public Perception

[02:06] Recalling the Past:
- The first episode on GLP-1 agonists aired five years ago when public and clinical attention was low.
- Interest surged after the introduction and outcomes of newer agents like semaglutide.
Main Driver of Interest:
- Weight loss potential in non-diabetic individuals represented a paradigm shift, taking GLP-1 RAs from "niche diabetes drugs" to agents with broader metabolic appeal.
"This was a drug that went from being kind of a niche diabetes drug to a drug that had far more appeal because it was now for the first time being looked at for weight loss in a non diabetic. And so that...kind of changed everything."
– Peter Attia [03:26]

2. The Problem: Muscle (Lean Mass) Loss with GLP-1 RAs

[04:17] Early Clinical Observations:
- Early data and Attia’s clinical experience showed disproportionately high lean mass loss in patients on GLP-1 RAs.
- In some cases, the lean-to-fat mass loss ratio was nearly 1:1, which is unusual and concerning.
"If a person lost 10 pounds, five of them would be fat and five of them would be lean, as it's characterized on DEXA...That's very different than if you're going to lose 10 pounds and 8 of it is fat and 2 of it is lean."
– Peter Attia [04:45]
DEXA Limitations:
- Lean mass on DEXA includes muscle, water, connective tissue, and even some internal organs, so these measurements can mislead interpretations about "muscle loss" specifically.

3. Media Hype, Scientific Debate, and Nuanced Interpretation

Public Warnings vs. Data:
- Increased media and scientific attention around 2021-2022 regarding muscle loss and “ozempic body” phenomena.
- Attia warns against both "fear-mongering" and overconfidence; the reality is nuanced and context-dependent.
Role of Modifiable Factors:
- Study and real-world outcomes depend significantly on patient counseling—especially regarding diet and resistance training.
- "Clinical trials are average, homogenized data," often not reflecting individualized coaching or interventions.
"You also have to be careful that you don't over interpret what you see in clinical trials...when you don't have insight into how those patients were necessarily counseled."
– Peter Attia [05:52]

4. Importance of Strength and Physical Function

While weight and body composition are important, the ultimate metric should be physical strength and function, not just DEXA-based lean mass numbers.

5. GLP-1 RAs and Bone Health

The episode promises discussion on the impact of these medications on bone mass and fracture risk, another underappreciated facet of risk.

6. New Agents: Retatrutide

Closing with a teaser on retatrutide, a next-generation peptide making headlines for its potency in weight loss and unknowns regarding its effect on muscle mass.
- Listeners are prompted to wonder: Will newer compounds be better or worse for muscle preservation?

Notable Quotes & Moments

On paradigm shift in GLP-1 use:

"...the implications of that were that this was a drug that went from being kind of a niche diabetes drug to a drug that had far more appeal because it was now for the first time being looked at for weight loss in a non diabetic. And so that, you know, kind of changed everything."
– Peter Attia [03:19]
On disproportionate muscle loss:

"People who were losing a lot of weight seemed to be losing much more lean mass than we normally saw in people who were going about weight loss using the normal variations of caloric restriction or dietary restriction or even time restriction."
– Peter Attia [04:21]
On the need for context in data interpretation:

"You don't want to discourage other doctors or patients from kind of experimenting with how to get better results than what the clinical trials showed."
– Peter Attia [06:21]

Timestamps for Important Segments

[00:39] Episode preview: major topics listed (GLP-1s, lean mass, DEXA, bone strength, strength/function, fat depots, at-risk populations, muscle/bone preservation, retatrutide).
[02:06 – 03:26] GLP-1’s evolution from diabetes to weight loss—public interest and regulatory context.
[04:17 – 05:12] Initial clinical experience of lean mass loss, ratio of fat vs. lean mass lost, and why this raised concern.
[05:21 – 06:21] Media/scientific discussion, nuance on patient counseling/adherence in real-world vs. clinical trial outcomes.
[06:39] Pending updates and next steps in understanding GLP-1 RA impact on muscle (episode ends/teaser for premium content).

Summary Takeaways

GLP-1 RAs revolutionized weight management by enabling significant weight loss in non-diabetic populations, but raised alarms about excessive lean (muscle) mass loss, especially early in their widespread use.
Interpreting lean mass loss requires caution: DEXA data is non-specific, and clinical trial populations may not reflect optimal patient support (i.e., lack of resistance training).
There’s a delicate balance between media attention, scientific concern, and practical application; the evidence demands both seriousness and nuance.
Preserving muscle and bone during pharmacologic weight loss should be a priority, and new agents like retatrutide will demand continued close scrutiny.
Ultimately, real-world outcomes can be improved with better patient education, nutritional support, and a focus on strength, not just the number on the scale.

To learn more about the latest data and practical approaches on GLP-1 RAs and muscle preservation, listeners are encouraged to seek out the full premium episode.

Loading summary

Transcript19 lines

[00:00]
Bob
Foreign.
[00:10]
Peter Attia
Hey everyone, welcome to a Sneak Peek, Ask Me Anything or AMA episode of the Drive podcast. I'm your host, Peter Attia. At the end of this short episode, I'll explain how you can access the AMA episodes in full, along with a
[00:23]
ton of other membership benefits we've created. Or you can learn more now by
[00:27]
going to Peteratti md.com forward/subscribe. So without further delay, here's today's sneak peek of the Ask Me Anything episode.
[00:39]
Welcome to ask me anything AMA episode 86. In today's AMA, we're going to look at the effects of GLP1 receptor agonists. So these are drugs like Ozempic, Wegovy and Zepbound. But specifically we're going to look at the impact they have on muscle. We're going to talk about how much lean mass people actually lose on these drugs and how that compares to weight loss by any other means. We're going to define exactly what lean mass is and how loss of lean mass on DEXA can actually mislead us. How these drugs impact bone mass and fracture risk. The all important effects of these drugs on strength and physical function, which probably should be the most important metric. The effect of these drugs on different fat depots across the body. Who's at most risk for lean mass loss, how to maintain muscle and bone strength on these drugs, and the initial insights of the effects of retatrutide, which is a drug I'm sure many of you have heard of as it's making its way through the peptide cesspool at the moment, but nevertheless will be an FDA approved drug in the not too distant future. And so people have lots of questions about how will retatrutide affect weight loss, but specifically its impact on muscle mass as well. So without further delay, I hope you enjoy AMA number 86.
[02:02]
Bob
Peter, welcome to another ama. How you doing?
[02:05]
Peter Attia
Very well, thank you.
[02:07]
Bob
Awesome. So for today we are going to talk GLP1 Agonist. And we did our first episode on this about five years ago. It was you and Bob and back then no one was really paying attention and no one really cared about that episode. And then about a year and a half later we did a second episode on them and and all of a sudden people really started to care. And so thinking back at this, what do you think it was about that second episode that got so many people's attention on this?
[02:38]
Peter Attia
I mean, if I were to think about it through the arc of the story of these drugs, I think it was obviously the impact on weight loss. I mean, my first foray into GLP1 agonists clinically was in 2014. So 12 years ago, I started experimenting with liraglutide in patients, found it relatively uninspiring and for that reason, given the cost and the logistics, kind of abandoned it. And I think when we did our first episode, we were already seeing the effects of semaglutide and how different it was. This was now the third generation of GLP1 agonists and we, we realized internally, frankly, I think by, I recall it being in the fourth quarter of 2020 that this was a step function change from the first two. And I just suspect in the answer to your question that I think there was just a time lag between when the public sort of came to realize that of course, the implications of that were that this was a drug that went from being kind of a niche diabetes drug to a drug that had far more appeal because it was now for the first time being looked at for weight loss in a non diabetic. And so that, you know, kind of changed everything. And at the time, you know, the FDA was really just looking at weight loss. They weren't looking at body composition. And so, you know, I think that's sort of, that was the beginning of the story.
[04:07]
Bob
Just to kind of double click on that, when you started to use these a little more, what were you seeing and what kind of jumped out that could have been problematic?
[04:18]
Peter Attia
Well, you know, what we saw in the early trials, and I think what we were seeing clinically five and a half years ago, was that people who were losing a lot of weight seemed to be losing much more lean mass than we normally saw in people who were going about weight loss using the normal variations of caloric restriction or dietary restriction or even time restriction. Although there's a bit of an asterisk
[04:45]
I could put there.
[04:47]
And it was almost a one to one ratio, which meant that if a person lost 10 pounds, five of them would be fat and five of them would be lean, as it's characterized on DEXA. And so that's, that's pretty relevant, right? So if you're going to lose ten pounds and half of it's lean and half of its fat, that's very different than if you're going to lose 10 pounds and 8 of it is fat
[05:10]
and 2 of it is, is lean.
[05:12]
So we were using DEXA scans, but obviously you could even clinically just look at people and see that something wasn't right with this form of weight loss.
[05:22]
Bob
And it seemed like around that time that kind of became a large part of the discussion kind of outside in the media. And there was a lot of stories about these drugs and some of the warnings, correct?
[05:35]
Peter Attia
Yeah, a lot of scientific papers began to raise that concern and I think that's very good in terms of raising public awareness about this, the potentially important side effects of these drugs. I think there's also been some fear mongering and speculating beyond what the data have shown. And I think I would add to that that as we learned, the manner in which the drugs are used and the manner in which the patients are counseled around the other modifiable behaviors, particularly with respect to their nutrition and exercise, can change the outcomes. So you also have to be careful that you don't over interpret what you see in clinical trials, which are, you know, average homogenized data when you don't have insight into how those patients were necessarily counseled. So it's, you know, it's, it's valuable to have that information, but you also don't want to be paralyzed by it, and you don't want to discourage other doctors or patients from kind of experimenting with how to get better results than what the clinical trials showed.
[06:39]
Bob
Yeah. And so now that we're a few years past that, what updates do we have around the story of GLP1s and muscle loss?
[06:50]
Peter Attia
Thank you for listening to today's Sneak Peek AMA episode of the Drive. If you're interested in hearing the complete version of this ama, you'll want to become a Premium member. It's extremely important to me to provide all of this content without relying on paid ads to do this. Our work is made entirely possible by our members and in return we offer exclusive member only content and benefits above and beyond what is available for free. So if you want to take your knowledge of this space to the next level, it's our goal to ensure members get back much more than the price of the subscription. Premium membership includes several benefits. First, comprehensive podcast Show Notes that detail every topic, paper, person and thing that we discuss in each episode. And the word on the street is Nobody's Show Notes Rival Hours. Second, monthly Ask Me Anything or AMA episodes. These episodes are comprised of detailed responses to subscriber questions typically focused on a single topic, and are designed to offer a great deal of clarity and detail on topics of special interest to our members. You'll also get access to the Show Notes for these episodes, of course. Third, delivery of our Premium newsletter, which is put together by our dedicated team of research analysts. This newsletter covers a wide range of topics related to longevity and provides much more detail than our free weekly newsletter. Fourth, access to our private podcast feed that provides you with access to every episode, including AMAs, sans the spiel you're listening to now and in your regular podcast feed. Fifth, the Qualys, an additional member only podcast we put together that serves as a highlight reel featuring the best excerpts from previous episodes of the Drive. This is a great way to catch up on previous episodes without having to go back and listen to each one of them and finally, other benefits that are added along the way. If you want to learn more and access these member only benefits, you can head over to Peterattiamd.com subscribe. You can also find me on YouTube, Instagram and Twitter, all with the handle Peterattiamd. You can also leave us a review on Apple Podcasts or whatever podcast player you use. This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional healthcare services, including the giving of medical advice. No doctor patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis or treatment. Users should not disregard or delay in obtaining medical advice from any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. Finally, I take all conflicts of interest very seriously. For all of my disclosures and the companies I invest in or Advise, please visit PeterAttiaMD.com for forward slash about where I keep an up to date and active list of all disclosures.